The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1421
July 22, 2013
View Complete Issue         Table of Contents 2019 
Citalopram, Escitalopram and the QT Interval
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Citalopram, Escitalopram and the QT Interval
July 22, 2013 (Issue: 1421)
In 2011, the FDA asked the manufacturers of the selective serotonin reuptake inhibitor (SSRI) citalopram (Celexa, and generics) to lower the maximum daily dosage of the drug because of a dose-related increase in the QT interval. Since then, some...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Citalopram, Escitalopram and the QT Interval
Article code: 1421b
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.